Blog

The latest thoughts from Medicines Law & Policy partners.

Decision on intellectual property waiver over Covid technology on hold till 2021; what are...

Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer. The...

Updated TRIPS Flexibilities Database

In January 2023, a number of cystic-fibrosis patient organisations asked the governments of Brazil, India, South Africa and Ukraine to invoke compulsory licensing and...

Wrapping Up 2017 – some noteworthy medicines law and policy events.

2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...

Trump Administration poses an unprecedented threat to life-saving health programmes 

On his first day in office, US President Trump issued several executive orders, one of which concerns US foreign aid. This order included a...

Drug Price Transparency Calls Move from South Africa to World Health Assembly

by Katrina Perehudoff and Jennifer Sellin Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...

New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments

A new briefing paper based on Medicines Law & Policy research outlines the legal instruments available for countries seeking to access key therapeutics to...

Corbyn’s Compulsory Licenses. Will they work?

On 24 September, Jeremy Corbyn, leader of the UK Labour party, announced a series of measures to bring medicines pricing in check and to...

EU Review of Pharmaceutical Incentives: Recommendations for Change

In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...

New reports offer evidence for extending the WTO Decision on TRIPS to Covid-19 therapeutics...

In February 2024, the 13th World Trade Organization (WTO) Ministerial Conference will take place. WTO Members are expected to decide whether to extend the...

WHO is an essential forum for debates on intellectual property and public health

Recently, Health Policy Watch reported that some European countries at the World Health Organization (WHO) Pandemic Agreement negotiations maintain that intellectual property negotiations belong...